CDLX vs. RCAT, YALA, RXT, DH, MGIC, RDVT, CRNC, PRCH, MTLS, and CCSI
Should you be buying Cardlytics stock or one of its competitors? The main competitors of Cardlytics include Red Cat (RCAT), Yalla Group (YALA), Rackspace Technology (RXT), Definitive Healthcare (DH), Magic Software Enterprises (MGIC), Red Violet (RDVT), Cerence (CRNC), Porch Group (PRCH), Materialise (MTLS), and Consensus Cloud Solutions (CCSI). These companies are all part of the "computer software" industry.
Cardlytics vs.
Red Cat (NASDAQ:RCAT) and Cardlytics (NASDAQ:CDLX) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
Cardlytics has a net margin of -93.55% compared to Red Cat's net margin of -232.62%. Red Cat's return on equity of -96.00% beat Cardlytics' return on equity.
In the previous week, Cardlytics had 11 more articles in the media than Red Cat. MarketBeat recorded 17 mentions for Cardlytics and 6 mentions for Red Cat. Red Cat's average media sentiment score of 0.21 beat Cardlytics' score of 0.05 indicating that Red Cat is being referred to more favorably in the media.
Red Cat has higher earnings, but lower revenue than Cardlytics. Red Cat is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
Red Cat has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
38.0% of Red Cat shares are held by institutional investors. Comparatively, 68.1% of Cardlytics shares are held by institutional investors. 21.5% of Red Cat shares are held by company insiders. Comparatively, 4.4% of Cardlytics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Red Cat presently has a consensus price target of $4.00, indicating a potential downside of 48.45%. Cardlytics has a consensus price target of $6.92, indicating a potential upside of 157.13%. Given Cardlytics' higher probable upside, analysts plainly believe Cardlytics is more favorable than Red Cat.
Cardlytics received 222 more outperform votes than Red Cat when rated by MarketBeat users. However, 100.00% of users gave Red Cat an outperform vote while only 57.25% of users gave Cardlytics an outperform vote.
Summary
Cardlytics beats Red Cat on 10 of the 19 factors compared between the two stocks.
Get Cardlytics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cardlytics Competitors List
Related Companies and Tools
This page (NASDAQ:CDLX) was last updated on 2/22/2025 by MarketBeat.com Staff